Bob Drakas is Vice President of ShangPharma Innovation with more than 20 years of experience leading therapeutic programs and cross functional teams. Bob previously served as the Executive Director of Business Development at ChemPartner Inc., a leading research organization providing services for the biopharmaceutical industry. In addition, he was part of the founding team for ShangPharma Investment Group. Earlier in his career, Bob served as senior analyst and senior research biochemist at Merck. He is board member of Blue Oak Therapeutics, Azkarra Therapeutics, ShangPharma Innovation, and board observer of Tilos Therapeutics, Mediar Therapeutics, and Evrys Bio.
Bob received his Ph.D. in molecular pharmacology from Thomas Jefferson University.